Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $29.17 Analyst target: $48.88 Upside: 67.57%
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company is headquartered in New York, New York.
See the full interactive analysis & chart →Informational only — not investment advice.